Hepion Pharmaceuticals (HEPA) Insider Trading & Ownership $0.62 -0.06 (-8.82%) (As of 10:26 AM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Hepion Pharmaceuticals (NASDAQ:HEPA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.95%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$15,350.00Number OfInsiders Selling(Last 12 Months)0 Get HEPA Insider Trade Alerts Want to know when executives and insiders are buying or selling Hepion Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address HEPA Insider Buying and Selling by Quarter Ad Behind the Markets❗ RSVP please!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Just click here and secure your spot! Hepion Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/27/2023Peter WijngaardDirectorBuy2,500$3.05$7,625.00 11/24/2023Peter WijngaardDirectorBuy2,500$3.09$7,725.00 (Data available from 1/1/2013 forward) HEPA Insider Trading Activity - Frequently Asked Questions Who is on Hepion Pharmaceuticals's Insider Roster? The list of insiders at Hepion Pharmaceuticals includes Peter Wijngaard, and Robert T Foster. Learn more on insiders at HEPA. What percentage of Hepion Pharmaceuticals stock is owned by insiders? 1.95% of Hepion Pharmaceuticals stock is owned by insiders. Learn more on HEPA's insider holdings. Which Hepion Pharmaceuticals insiders have been buying company stock? The following insiders have purchased HEPA shares in the last 24 months: Peter Wijngaard ($32,190.00), and Robert T Foster ($17,600.00). How much insider buying is happening at Hepion Pharmaceuticals? Insiders have purchased a total of 11,200 HEPA shares in the last 24 months for a total of $49,790.00 bought. Hepion Pharmaceuticals Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Compensation: $495.33kSharen PyatetskayaDirector of Investor RelationsDr. John Z. Sullivan-Bolyai (Age 76)Part-Time Consultant Dr. Stephen A. Harrison FACPM.D., Scientific Advisory Board Chair & Consultant Medical Director More Insider Trading Tools from MarketBeat Related Companies Mannatech Insider Transactions ProPhase Labs Insider Transactions Sensei Biotherapeutics Insider Transactions NRx Pharmaceuticals Insider Transactions Aspira Women's Health Insider Transactions Turnstone Biologics Insider Transactions Avalo Therapeutics Insider Transactions HCW Biologics Insider Transactions Indaptus Therapeutics Insider Transactions Eagle Pharmaceuticals Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:HEPA) was last updated on 11/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredFREE investing Class TOMORROW + 2 FREE BonusesOver the last 37 years on Wall Street, I've developed a unique investing strategy that allows me to find stock...Unstoppable Prosperity | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hepion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
